
## Elton Rexhepaj

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12174512/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery, 2011, 1, 54-67.	9.4	1,486
2	Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clinical Cancer Research, 2011, 17, 6083-6096.	7.0	330
3	SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas. American Journal of Surgical Pathology, 2011, 35, 937-948.	3.7	209
4	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nature Reviews Cancer, 2010, 10, 605-617.	28.4	181
5	Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Research, 2008, 10, R89.	5.0	113
6	Automated image analysis in histopathology: a valuable tool in medical diagnostics. Expert Review of Molecular Diagnostics, 2008, 8, 707-725.	3.1	104
7	Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. Clinical Cancer Research, 2008, 14, 2681-2689.	7.0	83
8	Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. BMC Cancer, 2013, 13, 175.	2.6	64
9	Tumour islet Foxp3 <sup>+</sup> T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. European Respiratory Journal, 2015, 46, 1762-1772.	6.7	56
10	RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer. Translational Oncology, 2011, 4, 212-IN1.	3.7	54
11	Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. BMC Cancer, 2010, 10, 125.	2.6	39
12	Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer, 2010, 10, 639.	2.6	38
13	Creation of a digital slide and tissue microarray resource from a multi-institutional predictive toxicology study in the rat: An initial report from the PredTox group. Experimental and Toxicologic Pathology, 2008, 60, 235-245.	2.1	37
14	SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Research, 2010, 20, 468-478.	1.2	35
15	Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Modern Pathology, 2011, 24, 708-719.	5.5	31
16	Selective Expression of Syntaxin-7 Protein in Benign Melanocytes and Malignant Melanoma. Journal of Proteome Research, 2009, 8, 1639-1646.	3.7	22
17	A Texture Based Pattern Recognition Approach to Distinguish Melanoma from Non-Melanoma Cells in Histopathological Tissue Microarray Sections. PLoS ONE, 2013, 8, e62070.	2.5	20
18	Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer. Cancer Genomics and Proteomics, 2007, 4, 121-34.	2.0	17

#	Article	IF	CITATIONS
19	Tissue Microarrays and Digital Image Analysis. Methods in Molecular Biology, 2011, 691, 97-112.	0.9	8